Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Minority Interest (2018 - 2021)

Sangamo Therapeutics (SGMO) has disclosed Minority Interest for 4 consecutive years, with -$938000.0 as the latest value for Q1 2021.

  • For Q1 2021, Minority Interest fell 856.45% year-over-year to -$938000.0; the TTM value through Mar 2021 reached -$938000.0, down 856.45%, while the annual FY2020 figure was -$868000.0, 569.19% down from the prior year.
  • Minority Interest hit -$938000.0 in Q1 2021 for Sangamo Therapeutics, down from -$868000.0 in the prior quarter.
  • Across five years, Minority Interest topped out at $739000.0 in Q4 2018 and bottomed at -$938000.0 in Q1 2021.
  • Average Minority Interest over 4 years is $0.0, with a median of $154500.0 recorded in 2019.
  • Year-over-year, Minority Interest plummeted 74.97% in 2019 and then crashed 856.45% in 2021.
  • Sangamo Therapeutics' Minority Interest stood at $739000.0 in 2018, then tumbled by 74.97% to $185000.0 in 2019, then crashed by 569.19% to -$868000.0 in 2020, then dropped by 8.06% to -$938000.0 in 2021.
  • According to Business Quant data, Minority Interest over the past three periods came in at -$938000.0, -$868000.0, and -$530000.0 for Q1 2021, Q4 2020, and Q3 2020 respectively.